Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers

Y Adachi, H Yamamoto, F Itoh, Y Hinoda, Y Okada, K Imai

Abstract

**Background/Aim**—Matrilysin is one of the matrix metalloproteinases that has a critical role in tumour invasion, and is often expressed in gastrointestinal cancers. The aim of this study was to examine the role of matrilysin in metastasis of human colorectal cancers.

**Patients (Subjects)/Methods**—The relation between matrilysin expression and Duke's type was investigated immunohistochemically in 83 surgically resected colorectal cancers, including five with liver metastasis. Moreover, the effects of matrilysin on the in vivo invasive and metastatic potential of colon cancer cells transfected with matrilysin cDNA were examined after subcutaneous injection into SCID mice.

**Results**—In 46% of primary and all of metastatic liver tumours, over 10% of cancer cells were stained positively for matrilysin. The expression of matrilysin correlated significantly with the presence of nodal or distant metastases (p<0.05). In addition, matrilysin transfectants formed invasive tumours and multiple liver metastases in SCID mice, without producing any significant difference in the subcutaneous tumour growth from mock transfectants. Casein zymography showed that the invading and metastasised tumours showed conspicuous matrilysin activity, which correlated with the number of metastatic lesions (p<0.001).

**Conclusions**—Matrilysin showed a correlation with metastasis in a cohort of 83 colorectal cancer patients and marked metastatic potential in human colorectal cancer xenografts, indicating that it may play a critical role in the metastatic pathway of colorectal cancers.

*Gut* 1999;45:252–258

Keywords: matrix metalloproteinase; matrilysin; MMP-7; colorectal cancer; metastasis; transfection; human

Matrix metalloproteinases (MMPs) have been implicated in tumour invasion as well as various normal processes of tissue remodelling, such as embryonic development, wound healing, trophoblast implantation, and organ morphogenesis.1-3 The proteolytic degradation of extracellular matrix by MMPs is one of the most important mechanisms in tumour cell invasion of basement membranes and the stromal matrix. The activity of MMPs is regulated by the conversion of latent proenzyme to the mature form and by a specific class of natural inhibitors, designated tissue inhibitor of metalloproteinases.4-5 MMPs are often active during tumour invasion, resulting in an excessive proteolytic degradation of the extracellular matrix.

Matrilysin (MMP-7) is a member of the MMP gene family and, after being activated, has a broad proteolytic activity against a variety of extracellular matrix substrates, including collagens, proteoglycans, elastin, laminin, fibronectin, and casein.6-4 Compared with other MMPs, matrilysin is distinguished by its low molecular mass (28 kDa) and its lack of a C-terminal domain. Matrilysin was identified first in postpartum rat uterus, and has been detected in several normal tissues, such as endometrium, bronchial mucosa, monocytes, and mesangial cells.6-8 It is also produced by malignant tumour cells including prostate, gastric, head and neck, lung, hepatocellular, and colorectal carcinomas.9-12

We have previously reported that matrilysin mRNA is overexpressed in colorectal cancers.10-11 It is noteworthy that only matrilysin and membrane type-1 MMP (MT1-MMP) are produced by colorectal cancer cells themselves, whereas the other MMPs, such as MMP-1 (interstitial collagenase), MMP-2 (gelatinase A), MMP-9 (gelatinase B), and MMP-13 (stromelysin-3), are secreted by stromal cells.9-11 15-22 Although matrilysin mRNA has been reported to increase with advancing colon cancer stage,22-23 matrilysin protein has not been studied. Meanwhile, the unique structure of matrilysin and its localising pattern suggest that this enzyme may function in a manner distinct from other MMPs and may contribute directly to the invasive potential of colorectal cancers. We have shown that transfection of matrilysin cDNA caused colon cancer cells to be more invasive, as assessed by an in vitro invasion assay,24 and that the degree of invasion correlated with the levels of its secretion.25 In addition, downregulation of this protease by introduction of antisense matrilysin cDNA made these cells less invasive.24

In this study, to assess the clinical impact of matrilysin protein expression in colorectal tumours, an immunohistochemical examination was performed on 78 surgically resected specimens with colorectal cancer and on five with liver metastasis. In addition, the effect of matrilysin on in vivo invasive and metastatic ability was examined six weeks after subcutaneous injection.

**Abbreviations used in this paper:** MMP, matrix metalloproteinase; MT1-MMP, membrane type-1 matrix metalloproteinase; SDS, sodium dodecyl sulphate.
euous transplantation with matrilysin transfected colon cancer cells into SCID mice. We report and discuss the effect of overexpression of matrilysin on colorectal cancer invasion and metastasis.

**Materials and methods**

**TISSUES, CELLS, AND ANIMALS**

All tissue samples with human colon cancer were obtained surgically. Each sample was fixed by the AME method and embedded in paraffin wax. A human colon cancer cell line CHC-Y1 was obtained from the Japanese Cancer Research Resources Bank (Osaka, Japan). Cells were maintained in RPMI 1640 containing 10% fetal bovine serum at 37°C in a humidified atmosphere of 5% CO2, in air. Specific-pathogen-free female CB17/ICR Scid Jcl mice (six weeks old) were purchased from Clea Japan (Tokyo, Japan). They were maintained in a specific-pathogen-free environment, and their care and use were according to our university’s guidelines.

**IMMUNOHISTOCHEMISTRY**

The sections were dewaxed in xylene and rehydrated in alcohol. The endogenous peroxidase activity was suppressed by a solution of hydrogen peroxide in methanol for 20 minutes. After being rinsed twice in phosphate buffered saline, the sections were incubated with non-immune rabbit serum for 20 minutes. The slides were treated with primary monoclonal antibody diluted in blocking solution for 18 hours at 4°C. After being washed three times in phosphate buffered saline, the sections were treated with peroxidase conjugated rabbit anti-mouse immunoglobulin P-0260 (1:40 dilution; Dako, Glostrup, Denmark) for 30 minutes. The sections were developed in 3,3'-diaminobenzidine (0.6 mg/ml) in 0.05 M Tris/HCl (pH 7.5) containing 0.01% hydrogen peroxide at room temperature. The slides were counterstained in Mayer’s haematoxylin and mounted.

Anti-matrilysin monoclonal antibody 141-7B2 (mouse IgG1)27 was generously provided by Fuji Chemical Industries (Toyama, Japan). This monoclonal antibody shows no cross reactivity with other MMPs, including MMP-1, MMP-2, MMP-3 (stromelysin-1), MMP-8 (neutrophil collagenase), and MMP-9.27 Monoclonal antibody AI-206 (mouse IgG1), an anti-idiotypic antibody, was used as negative control. The concentration of both primary antibodies used for immunostaining was 10 µg/ml. Immunostaining signals were scored independently by two observers. The scores were calculated as the number of stained cells divided by the total number of carcinoma cells.

**CELL PROLIFERATION ASSAY**

Proliferation of tumour cells in vitro was measured using the colorimetric 3-(4,5-dimethylthiazol)-2,5-diphenyltetrazolium bromide assay (Sigma, St Louis, Missouri, USA). Cells were harvested with 0.25% trypsin treatment, resuspended in medium alone, and plated in 96-well plastic tissue plates at 1 × 104 cells in 0.1 ml per well. Five identical plates were set up for each cell line, and the cell number was determined after three different incubation periods (0, 12, 24, and 48 hours).

**CELL MOTILITY ASSAY**

An assay based on the ability of cells to clear colloidal gold particles, by phagocytosis, from the substratum as the cells move on it and form “phagokinetic tracks” was performed.28 Briefly, 2000 cells were seeded on glass coverslides coated with bovine serum albumin and colloidal gold and were placed in 35 mm tissue culture dishes containing 2 ml RPMI 1640. After 24 hours, the phagokinetic tracks were visualised by observing the coverslides with a microscope. Several fields were photographed, and areas cleared of gold particles by at least 35 individual cells were measured.

**DNA TRANSFECTION**

DNA transfection was performed essentially as described previously.29 A full length cDNA encoding human matrilysin was subcloned into the eukaryotic expression vector pcDNA I neo (Invitrogen, San Diego, California, USA). Transfection of CHC-Y1 cells was performed with LipofectAMINE (Gibco, Gaithersberg, Maryland, USA) following the manufacturer’s protocol. After a few weeks of G418 selection, individual colonies were picked and expanded for further analysis. Transfectants containing the selection neoplasmyd pcDNA I alone were used as controls.

**NORTHERN BLOT ANALYSIS**

Northern blot analysis was performed essentially as described previously.30 Total RNA was isolated from cells by the acid guanidinium thiocyanate/phenol/chloroform method; 10 µg was used for the northern blot analysis. The membrane was hybridised with a matrilysin cDNA probe labelled by the random primer method in 50% formamide/5 × Denhardt’s solution/3 × SSC (where 1 × SSC is 0.15 M NaCl/0.015 M sodium citrate)/100 mg/ml salmon sperm DNA/1% sodium dodecyl sulphate (SDS) at 42°C overnight. After a wash, the membrane was exposed to x-ray film at −70°C with an intensifying screen. A β-actin cDNA probe was used to control the quantity of loading and integrity of total RNA in each lane.

**ZYMOGRAPHIC ANALYSIS**

Zymography was performed essentially as described previously.12 Tissues were cut up and homogenised in an SDS/polyacrylamide gel electrophoresis sample buffer containing 10% glycerol, 1% SDS, and bromophenol blue. Protein content was measured against bovine serum albumin using the Braford method.29 Zymography in SDS/polyacrylamide gels containing casein was performed for matrilysin. Equal amounts of protein of homogenised tissues or the culture medium from cells grown for 24 hours in serum-free medium were electrophoresed in a 10% polyacrylamide gel embedded with 1 mg/ml casein. After electrophoresis, the gels were washed in 2.5% Triton
X-100 for one hour to remove SDS. The gels were then incubated for 18 hours at 37 °C in 50 mM Tris/HCl (pH 7.5), containing 10 mM CaCl₂ and 0.02% NaN₃, stained with Coomassie brilliant blue and then destained.

TUMOUR XENOGRAFT MODEL

Cells were harvested from subconfluent cultures by 0.25% trypsin treatment, and their viability was greater than 95% as assessed by trypan blue exclusion assays. They were inoculated subcutaneously into the hip region of mice at a concentration of 1 × 10⁶ cells per mouse. The animals were observed daily for tumour growth, and subcutaneous tumours were measured using a caliper every seven days. Tumour volumes were calculated using the formula: tumour volume = (length × width²)/2.

Eight mice from each group were killed by cervical dislocation when the first mouse appeared lethargic (day 44), and tumours were examined grossly and histologically. The livers were excised and metastases were counted. To investigate the metastatic potential of the tumours derived from parental cell CHC-Y1, five mice were killed and examined from 57 to 103 days after injection.

STATISTICAL ANALYSIS

The results are presented as means (SE) for each sample. The statistical significance of differences was determined by the χ² test for the relation between immunohistochemical expression of matrilysin and clinicopathological factors or Dukes's stage and by the Mann-Whitney U test for the tumour xenograft model. p values of less than 0.05 were considered to indicate statistical significance.

All data were calculated with the Statview 4.02 statistical software package (Abacus Concepts, Berkeley, California, USA) run on a Macintosh personal computer (Apple Computers, Cupertino, California, USA).

Results

IMMUNOHISTOCHEMICAL STUDY OF MATRILYSIN EXPRESSION IN RESECTED COLON CANCERS

Seventy eight sections from human colorectal cancers were analysed by immunostaining with an anti-matrilysin monoclonal antibody 141-7B2. The antibody stained cytoplasm and cell membranes of cancer cells (fig 1). The positively stained cells were distributed heterogeneously in the tumour nest and were often located at the invasive front. The stromal com-

Table 1. Relation between immunohistochemical expression of matrilysin and Dukes’s classification

<table>
<thead>
<tr>
<th></th>
<th>A + B</th>
<th>C + D</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤10%</td>
<td>21</td>
<td>21</td>
<td>42</td>
</tr>
<tr>
<td>&gt;10%</td>
<td>10</td>
<td>26</td>
<td>36</td>
</tr>
<tr>
<td>Total</td>
<td>31</td>
<td>47</td>
<td>78</td>
</tr>
</tbody>
</table>

p<0.05, χ² test.
ponents, except for some monocytes, were not stained with the antibody. Benign tissues adjacent to the neoplasm showed no immunoreactivity, indicating that the expression of matrilysin is restricted to malignant cells. In 36 cases (46%), over 10% of cancer cells were stained positively for matrilysin. These cases were significantly more common in Dukes’s type C+D (26/47, 55%) than in A+B (10/31, 32%; p<0.05, χ² test; table 1). With regard to each clinicopathological variable, matrilysin only correlated with nodal metastasis (24/42 in n(+) v 12/36 in n(−); p<0.05, χ² test).

All five specimens with liver metastasis were stained with the matrilysin monoclonal antibody (fig 1). As regards benign liver tissues, expression of matrilysin was observed in the epithelial cells of bile ducts, but not in hepatocytes. In four liver metastatic lesions that were stained simultaneously with the corresponding primary colon cancers, two metastatic nests were apparently immunostained more strongly than the primary site (fig 1).

TRANSFECTION OF MATRILYSIN cDNA INTO COLON CANCER CELLS
As the colon cancer cell CHC-Y1 expressed matrilysin mRNA at a level undetectable by northern blot analysis, this cell line was used for the transfection experiments. The matrilysin transfected cells showed various levels of matrilysin mRNA whereas it was not detected in mock transfectants (fig 2A). The enzymic activity of matrilysin was examined by casein zymography. Matrilysin transfected cells secreted both zymogen (29 kDa) and the activated form (19 kDa) into the culture medium, but neither form was produced by parental cells or mock transfectants (fig 2B). Clones CHC-Mat-4 (fig 2, lane 5) and CHC-Mat-6 (lane 7) were used as sublines expressing high and moderate levels of matrilysin respectively.

In vitro growth of both CHC-Mat-4 and CHC-Mat-6 did not differ significantly from that of CHC-Y1 or mock transfectants (fig 3A). Also, in vitro motility of both matrilysin transfected sublines was equivalent to that of mock transfectants or parental cells (fig 3B).

TUMORIGENICITY AND INVASIVENESS OF MATRILYSIN TRANSFECTANTS
All sublines of CHC-Mat-4, CHC-Mat-6, mock transfectant, and CHC-Y1 formed tumours at the transplanted subcutaneous site.
in SCID mice. The size of tumours derived from matrilysin transfectants was not significantly different from that of tumours derived from mock transfectants (fig 4). All tumours derived from matrilysin transfectants had invaded the underlying muscle tissues six weeks after injection, while neither the mock transfectants nor the parental cells showed any invasion (fig 5A,B, table 2). The invasive potential of CHC-Y1 cells per se seems to be very low because three of five SC tumours showed faint invasion of a muscle layer with longer incubation periods (9–15 weeks) after implantation with parental cells into SCID mice. The subcutaneous tumours derived from CHC-Mat-4 and CHC-Mat-6 were shown to express matrilysin mRNA, whereas it remained negative in the tumours derived from parental cells and mock transfectants. The expression levels of MMP-2 mRNA were similar among subcutaneous tumours derived from each subline (data not shown). Both latent and activated forms of matrilysin were secreted in the tumours derived from the matrilysin transfectants. CHC-Mat-4 showed higher matrilysin activity than CHC-Mat-6, reflecting their relative message levels (fig 6A). It is of note that the ratio of active to latent matrilysin was higher in the subcutaneous tumours than in the culture medium of matrilysin transfectants (figs 2B and 6A).

**LIVER METASTASIS SUBSEQUENT TO SUBCUTANEOUS INJECTION**

In spite of no significant differences in subcutaneous tumour growth, multiple liver metastases were seen in the mice injected with matrilysin transfectants six weeks after injection (fig 5C,D, table 2). No metastatic lesion was observed in mock transfectants or parental cells at all, even though the mice were killed 9 to 15 weeks after implantation. The number of metastatic liver nodules in mice transplanted with the CHC-Mat-4 (mean 14.5, range 9–19) was greater than that with the CHC-Mat-6 (mean 6.0, range 4–8; p = 0.0007, Mann-Whitney U test; table 2). The metastatic liver nodules expressed matrilysin, but normal murine liver did not secrete it (fig 6B). This enzyme was effectively activated in the metastatic lesions as well as in primary subcutaneous tumours, whereas matrilysin secreted into

---

**Table 2 Invasion and metastasis after subcutaneous injection of tumour cells into SCID mice**

<table>
<thead>
<tr>
<th>Cell line</th>
<th>Time of autopsy (days)</th>
<th>Primary tumour</th>
<th>Liver metastasis</th>
<th>Mean number of tumour nodules/mouse</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Incidence</td>
<td>Invasion of muscle layer</td>
<td>Incidence</td>
<td></td>
</tr>
<tr>
<td>CHC-Y1</td>
<td>44</td>
<td>8/8</td>
<td>0/8</td>
<td>0/8</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHC-Mat-4</td>
<td>57–103</td>
<td>5/5</td>
<td>3/5</td>
<td>0/5</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHC-Mat-6</td>
<td>44</td>
<td>8/8</td>
<td>8/8</td>
<td>8/8</td>
<td>14.5 (1.3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>9–19</td>
</tr>
<tr>
<td>CHC-mock</td>
<td>44</td>
<td>8/8</td>
<td>0/8</td>
<td>0/0</td>
<td>0</td>
</tr>
</tbody>
</table>

*Significantly different from CHC-Mat-4, p = 0.0007 (Mann-Whitney U test).
Figure 6  Primary and metastatic tumours of SCID mice were analysed by zymography as described in Materials and methods. (A) Casein zymography showed that primary subcutaneous tumours derived from the two matrilysin transfectants produced matrilysin, the active form (19k) of which was much more abundant than the latent form (29k). (B) Casein zymography of liver showed that activated matrilysin was effectively expressed in metastatic lesions but neither form of matrilysin was detected in normal murine liver.

Discussion

Firstly, we have shown that immunohistochemical expression of matrilysin in colon cancer tissue is more common in Dukes’s type C+D than in type A+B, as well as in nodal metastasis cases than in negative ones, indicating that it correlates with the presence of some metastases. This result is supported by previous reports in which matrilysin mRNA expression was greater in colorectal cancer than in paired normal colorectal mucosa, and its message level increased with Dukes’s type.11–23 Metastatic liver tumours, moreover, expressed matrilysin equally to or more strongly than the primary site, supporting a hypothesis that matrilysin plays a crucial role in colon cancer metastasis. In most of the colorectal cancer tissues, matrilysin was not stained homogeneously in the tumour nodules. Moreover, matrilysin staining in cancer cells was quite often observed at the invasive front, suggesting that it may be induced by tumour-host interactions, which are considered to be very important in tumour progression.11,13–15

We have shown that overexpression of matrilysin made the colon cancer cell CHC-Y1 alter its in vivo invasive potential, in spite of having no significant influence on the character of tumour cell growth or motility. This observation confirms our previous report that matrilysin modulates in vitro invasive potential of colon cancer cells,23 and another report on prostate cancer cells in vivo.32 We have also obtained evidence that induction of matrilysin enhanced the metastatic potential of colon cancer cells. Furthermore, the ratio of active to latent matrilysin in tumours in vivo increased in contrast with the cells in culture. These results suggest that not only expression but also activation of matrilysin enables these cells to metastasise efficiently. This is supported by the fact that the number of liver metastatic lesions was increased in proportion to matrilysin activity. Activation of MMPs is one of the most critical steps in controlling their enzyme activity and is proposed to be mediated by host-tumour interactions and by several proteinases, such as serine proteinases, stromelysin-1, and MT1-MMP.11,30–32 Our results suggest that not only expression but also activation of matrilysin overexpression in vivo. One is that it is due to the direct effects of matrilysin, such as activation of gelatinases A and B.11,34–35 Another is that it occurs through indirect effects of matrilysin, such as activation of gelatinases A and B.11,34–35 Our preliminary data showed no apparent differences in gelatinase activity between the tumours, suggesting that the latter explanation is unlikely. However, we cannot rule out other indirect effects of matrilysin, such as an activation of other MMPs or inactivation of serine proteinase inhibitors.

Matrilysin transfectant SW480 colon cancer cells were reported to not metastasise after transplantation into nude mice, in spite of their enhanced in vitro invasive potential.30 One of the reasons for this inconsistency may be an indirect effect of matrilysin overexpression in vivo. Although there is no available information on SW480 cells. Nevertheless, the discrepancy suggests the latter explanation may not be sufficient to acquire the full ability to metastasise. The human colon cancer CHC-Y1 cell was able to invade the muscle layer when subcutaneous tumours were allowed to grow for long periods. This cancer cell, however, does not appear to metastasise readily to the liver in SCID mice, because CHC-Y1 produced liver metastases in only one out of 10 mice, four to seven weeks after intrasplenic inoculation (unpublished data). Matrilysin may modify the character of the cell in mice, in such a way that invasion and then metastasis are made possible. Taking the recent reports that matrilysin increases the tumorigenic potential of neoplastic colon cells into consideration, this proteinase may affect the cell in an as yet unknown manner. A greater understanding of this molecule is required.

In summary, immunohistochemical expression of matrilysin correlated with Dukes’s classification in colon cancer specimens, and introduction of matrilysin into colon cancer cells markedly upregulated their in vivo invasive and metastatic potential, suggesting that matrilysin may play a critical role in colorectal cancer progression.
This work was supported by grants-in-aid from the Japanese Ministry of Education, Science, Sports and Culture (to F I, Y H, and K I) and the Japanese Ministry of Health and Welfare (to F I, Y H, and K I). The authors thank Dr David P Carbon, Vandelbi Cancer Center, for editorial assistance, Fuji Chemical Industries for the gift of anti-matriylisin monoclonal antibody, and the Japanese Cancer Research Funds Bank for providing a cell.

Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers

Y Adachi, H Yamamoto, F Itoh, Y Hinoda, Y Okada and K Imai

Gut 1999 45: 252-258
doi: 10.1136/gut.45.2.252

Updated information and services can be found at:
http://gut.bmj.com/content/45/2/252

These include:

References

This article cites 35 articles, 11 of which you can access for free at:
http://gut.bmj.com/content/45/2/252#BIBL

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

Colon cancer (1547)
Hepatic cancer (474)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/